

ASX / Media Release

5 October 2009

RHT: Resonance Health announces Board Appointment of Simon Panton

Resonance Health is pleased to announce the appointment of Simon Panton to the Board as nonexecutive director of the Board, effective immediately. Mr Panton has been a strong supporter of the Company and the FerriScan[®] technology over a number of years and is a major shareholder of Resonance Health. Mr Panton brings skills in business and marketing having run his own successful business.

Resonance Health is delighted Mr Panton has joined the board at an exciting time in the company's development with commercial sales and international interest in FerriScan[®] increasing and with the company posting its first full year profit.

Resonance is investigating the next generation of tests for liver disorders and developing improvements to the successful FerriScan[®] test.

By Order of the Board
Resonance Health Limited

For further information please contact:

Resonance Health
Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@resonancehealth.com

Eva O'Malley
Company Secretary
T: +61 8 9286 5300
E: evao@ferriscan.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing core laboratory services utilising advanced medical technology for the analysis of medical images. Its patented technology FerriScan[®], provides a safe and accurate alternative for measuring liver iron concentration, a significant issue for patients with iron overload. Initial commercialisation of FerriScan[®] has focused on pharmaceutical companies developing drug therapies to treat iron overload, and is now being extended to the broader international clinical community.